Anti-HER2 Antibody-drug Conjugate BAT8001 clinical trials
How each study uses Anti-HER2 Antibody-drug Conjugate BAT8001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BAT8001
- 1
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Anti-PD-1 Monoclonal Antibody BAT1306 (1)
Studies
Open first, then newest update. How each study uses Anti-HER2 Antibody-drug Conjugate BAT8001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for PatientsStatus unknownPhase 1Bio-Thera SolutionsNCT04189211Written as BAT8001How we know
- The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast CancerStatus unknownPhase 3Bio-Thera SolutionsNCT04185649Written as BAT8001 for injectionHow we know
- A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid TumorStatus unknownPhase 1/2Bio-Thera SolutionsNCT04151329Written as BAT1306 and BAT8001 2.4mg/kgHow we know